Cytokine-Based Tumor Immunotherapy

The use of immunostimulant monoclonal antibodies has revolutionized the treatment of cancer. To obtain the maximum potential from these treatments that stimulate the immune system, it is necessary to develop drugs based on molecules that mediate communication between the cells of the immune system: cytokines. The development of safe, effective drugs based on cytokines requires a thorough knowledge of the biology of these molecules and the design of sophisticated strategies to improve their therapeutic properties. This is the goal of the cytokine-based tumor immunotherapy group.

Fecha de actualización: Enero 2019

Active projects

  • Explotando SR-B1 para el desarrollo de nuevos fármacos inmunomodulares para potenciar la inmunoterapia del cáncer

    Convocatoria: Proyectos de I+D en Salud. AES 2016
    Título: “Explotando SR-B1 para el desarrollo de nuevos fármacos inmunomodulares para potenciar la inmunoterapia del cáncer”
    Referencia: PI16/00668
    I. P.: Pedro Berraondo López
    Duración: 3 años
    F. Inicio: 01/01/2017 F. Fin: 31/12/2019
    Financiado: Por el Instituto de Salud Carlos III y cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa”. 


"The identification of new targets to potentiate immune responses to cancer is the first step toward safer and more effective antitumor drugs", Dr. Pedro Berraondo.

Contact

Contact:
Cristina López
Avda. Pío XII, 55
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 6021
clopezg@unav.es